Oncopeptides AB (publ) announced that more information regarding the formal request from the U.S. Food and Drug Administration (FDA) to voluntarily withdraw Pepaxto's approval in the U.S has been made available by the FDA. The public docket contains, among other documents, a detailed appeal document outlining Oncopeptides' arguments for why Pepaxto should remain on the U.S. market as an important treatment option for multiple myeloma patients in later lines of treatment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.34 SEK | +14.97% | +12.08% | -56.40% |
04-15 | Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain | CI |
04-04 | Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.40% | 67.6M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ONCO Stock
- News Oncopeptides AB
- Oncopeptides AB Announces Information Regarding the Formal Request from the U.S. Food and Drug Administration